Chlorphentermine

From Self-sufficiency
Revision as of 15:10, 26 May 2010 by Meodipt (Talk) (See also)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Chlorphentermine
File:Chlorphentermine.svg
Systematic (IUPAC) name
1-(4-chlorophenyl)-2-methylpropan-2-amine
Clinical data
Routes of
administration
Oral, Insufflated, Rectal
Legal status
Legal status
  • Schedule III (US)
Pharmacokinetic data
Biological half-life 40 hours
Excretion Renal
Identifiers
CAS Number 461-78-9 151-06-4 (HCl)
ATC code A08AA (WHO)
PubChem CID 10007
ChemSpider 9613
Synonyms p-Chloro-α,α-dimethylphenethylamine
Chemical data
Formula C10H14ClN
Molar mass 183.68 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Chlorphentermine (trade names Apsedon, Desopimon, Lucofen) is an appetite suppressant. Developed in 1962, it is the 4-chloro derivative of the better known appetite suppressant phentermine,[1] which is still in current use.

Chlorphentermine itself is a relatively weak stimulant with little abuse potential, but is classed as a Schedule 3 drug in the USA due mainly to its similarity to other appetite suppressants such as diethylpropion which have been more widely abused. It is no longer used due mainly to safety concerns, as it has a serotonergic effects profile similar to other withdrawn appetite suppressants such as fenfluramine and aminorex which were found to cause pulmonary hypertension and cardiac fibrosis following prolonged use.[2]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


pl:Chlorfentermina
  1. Gylys JA, Hart JJ, Warren MR. Chlorphentermine, a new anorectic agent. Journal of Pharmacology and Experimental Therapeutics. 1962 Sep;137:365-73.
  2. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation. 1999 Aug 24;100(8):869-75.